U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314346) titled 'Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone' on Dec. 18, 2025.
Brief Summary: Drug-drug interaction study between Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Volunteer Study
Intervention:
DRUG: Buprenorphine/Naloxone + BEM/RZR
Day -5 to Day -1:buprenorphine/naloxone as individualized QD doses up to 24mg/6mg.
Day 1 to Day 5:Individualized QD doses of buprenorphine/naloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine/naloxone + BEM 550mg/RZR 180mg QD.
...